Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announces it has completed its acquisition of SPR Therapeutics, Inc. (SPR), a privately held medical technology company and recognized leader in short-term, percutaneous peripheral nerve stimulation (PNS) therapies for chronic and acute pain management. The acquisition is valued at $650 million, consisting of an upfront cash payment. SPR’s FDA-cleared SPRINT® PNS System is a short-term therapy designed to provide pain relief using a 60-day, minimally invasive treatment approach that does not require a permanent implant.
Read the full article: Medtronic Completes Acquisition of SPR, Expanding Patient Access to Minimally Invasive, Non-Opioid Treatment of Chronic and Acute Pain //
Source: https://www.prnewswire.com/news-releases/medtronic-completes-acquisition-of-spr-expanding-patient-access-to-minimally-invasive-non-opioid-treatment-of-chronic-and-acute-pain-302827532.html